渤健公司 BIIB 深 沪
等待开盘 10-08 09:30:00 美东时间
222.15
-0.740
-0.33%
华盛通- 最 高228.00
- 今 开222.93
- 成交量 129.81万股
- 最 低 221.40
- 昨 收 222.89
- 总市值 328.24亿
- 52周最高 230.49
- 市盈率 静 25.28
- 换手率 0.88%
- 52周最低 138.00
- 委 比 -61.54%
- 总股本 1.48亿
- 历史最高 468.55
- 量 比 1.07
- 振 幅 2.96%
- 历史最低 61.605
- 每 手 1
- 风险率 20.41%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多内部人交易｜渤健披露一笔股票增持，金额约4177.72美元
美股上市公司渤健（BIIB）披露一笔内部人股票交易。文件显示，公司内部人Godbout (Sean)（Officer）2026-10-02增持公司股票，交易金额...
10-07 07:01
Biogen’s Salanersen Trial Strengthens Its SMA Pipeline Outlook
Biogen Inc. ($BIIB) announced an update on their ongoing clinical study. Biogen...
10-03 00:31
Biogen Announces Data From Phase 2 Part Of Its Current AMETHYST Phase 2/3 Trial Of Litifilimab In Participants With Cutaneous Lupus Erythematosus Demonstrates 27.2% Of Patients At Week 52 Achieve Clinical Endpoint Of Clear Or Utmost Clear Skin; Litifilimab Seen To Be Generally Well Tolerated
Biogen Inc. (NASDAQ:BIIB) today announced 52-week results from the Phase 2 part of the ongoing AMETHYST Phase 2/3 study (Part A) of litifilimab in people living with cutaneous lupus erythematosus (CLE). The updated results, presented at the European Academy of Dermatology and Venereology (EADV) 2026...
10-02 23:26
Biogen’s Litifilimab Demonstrates Rapid and Durable Efficacy in New 52-Week Phase 2 Data from Ongoing Phase 2/3 AMETHYST Study, Reinforcing Its Potential as a First-in-Class Therapy for Cutaneous Lupus Erythematosus
Biogen announced 52-week Phase 2 results for litifilimab in cutaneous lupus erythematosus (CLE), showing continued improvement in skin clearance and disease activity. Over a quarter of participants achieved clear or almost clear skin, with rapid onset of benefits within four weeks for those switching from placebo. Litifilimab's safety profile remained consistent with no new safety signals. Positive results support its potential as a first-in-clas...
10-02 15:20
Biogen Announces Publication Of Phase 3 VALIANT Adolescent Subgroup Data In CJASN Demonstrating 75% Proteinuria Reduction For EMPAVELI In Rare Kidney Diseases
EMPAVELI-treated adolescents achieved a 75% relative reduction in proteinuria within 6 months versus placebo EMPAVELI is the only approved treatment for adolescents with C3G and primary IC-MPGN, based on VALIANT study Publication follows a recent FDA label update to expand EMPAVELI’s indication to ...
09-18 04:17
LEQEMBI® Pen (Subcutaneous Formulation of LEQEMBI®) Approved in Japan for the Treatment of Early Alzheimer’s Disease
Eisai and Biogen announce the approval of LEQEMBI Pen in Japan, a subcutaneous formulation of the anti-amyloid beta antibody LEQEMBI, allowing at-home administration for Alzheimer's disease. LEQEMBI Pen enables weekly self-injection or administration by a caregiver, offering greater flexibility and reducing the burden of hospital visits. This marks the third country to approve the SC formulation, which has shown similar efficacy and safety to IV ...
09-16 06:00
特朗普提名的“美国首席医生”，持仓烟草、快餐及碳酸饮料股
周四公布的财务披露文件显示，美国总统唐纳德·特朗普提名的医务总监（Surgeon General）候选人妮可·萨菲尔持有烟草企业菲利普莫里斯国际，以及怪物饮...
09-12 10:21
美股大行评级 | 齐声看好医药股！礼来、强生、默沙东目标价均获上调；小摩大幅上调Meta目标价至820美元
今日重点评级关注：康托·菲茨杰拉德：维持SOL Strategies"超配"评级，目标价从2.8美元升至6.2美元；康托·菲茨杰拉德：维持Sui Group Holdings"超配"评级，目标价从1.7美元升至3.4美元
09-11 14:30
Stoke, Biogen Report Lasting Seizure Reductions In Dravet Syndrome Study
Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, and Biogen Inc. (NASDAQ:BIIB) today announced presentations of data at the 16th European Epilepsy Congress (EEC), taking place September 5-9...
09-04 16:00
美股大行评级 | 大行齐上调AI应用股目标价！Adobe、CRWD等获看好，慧与科技绩后现多空分歧
今日重点评级关注：BTIG：维持Climb Bio"买入"评级，目标价从20美元升至32美元；巴克莱：维持Alpha Tau Medical"超配"评级，目标价从17美元升至30美元
09-04 12:30
